Literature DB >> 15060172

How many mutant p53 molecules are needed to inactivate a tetramer?

Wan Mui Chan1, Wai Yi Siu, Anita Lau, Randy Y C Poon.   

Abstract

The tumor suppressor p53 is transcription factor composed of four identical subunits. The majority of the mutations in p53 are missense mutations that impair DNA binding. On the other hand, the p53-related p63 and p73 genes are rarely mutated, but many cell types express natural variants lacking the N-terminal transactivation domain (NDelta). Compelling evidence indicates that both the DNA binding-defective and NDelta mutants can impair the function of wild-type p53 in a dominant-negative manner. Interestingly, it is uncertain how many mutant subunit(s) a p53 tetramer can tolerate. In this study, we first made theoretical predictions based on the number of mutant p53 monomers needed to inactivate a tetramer and then tested how well the experimental data fit the predicted values. Surprisingly, these experiments reveal that DNA binding-defective p53 mutants (R249S and R273H) are very ineffective in impairing the transcriptional activity of p53: at least three mutants are required to inactivate a tetramer. In marked contrast, p53NDelta is a very potent inhibitor of p53: one NDelta subunit per tetramer is sufficient to abolish the transcriptional activity. DNA binding is not necessary for the NDelta proteins to inactivate p53. Similarly, NDelta variants of p63 and p73 are also powerful inhibitors of members of the p53 family. These results have important implications for our thinking about the mechanism of tumorigenesis involving missense p53 mutants or the N-terminally truncated isoforms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060172      PMCID: PMC381690          DOI: 10.1128/MCB.24.8.3536-3551.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

Review 1.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

Review 2.  p53: at the crossroads of molecular carcinogenesis and risk assessment.

Authors:  C C Harris
Journal:  Science       Date:  1993-12-24       Impact factor: 47.728

3.  Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype.

Authors:  T Frebourg; M Sadelain; Y S Ng; J Kassel; S H Friend
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

4.  Interaction of p53 with its consensus DNA-binding site.

Authors:  Y Wang; J F Schwedes; D Parks; K Mann; P Tegtmeyer
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

5.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.

Authors:  P D Jeffrey; S Gorina; N P Pavletich
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

6.  Tumour-suppressor genes. X-rays strike p53 again.

Authors:  B Vogelstein; K W Kinzler
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

7.  MDM2 and MDMX bind and stabilize the p53-related protein p73.

Authors:  W M Ongkeko; X Q Wang; W Y Siu; A W Lau; K Yamashita; A L Harris; L S Cox; R Y Poon
Journal:  Curr Biol       Date:  1999 Jul 29-Aug 12       Impact factor: 10.834

8.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

9.  Mutant p53 proteins behave in a dominant, negative fashion in vivo.

Authors:  M Hachiya; A Chumakov; C W Miller; M Akashi; J Said; H P Koeffler
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

10.  Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.

Authors:  K Forrester; S E Lupold; V L Ott; C H Chay; V Band; X W Wang; C C Harris
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

View more
  63 in total

1.  An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.

Authors:  Susan M Mendrysa; Keiko Akagi; Jean Roayaei; Wen-Hui Lien; Neal G Copeland; Nancy A Jenkins; Robert N Eisenman
Journal:  Genes Cancer       Date:  2010-05

Review 2.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

3.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

4.  Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Authors:  Jiangtao Lei; Ruxi Qi; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  Phys Chem Chem Phys       Date:  2016-03-21       Impact factor: 3.676

5.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

Review 6.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 7.  Neomorphic mutations create therapeutic challenges in cancer.

Authors:  V Takiar; C K M Ip; M Gao; G B Mills; L W T Cheung
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

Review 8.  Versatile functions of p53 protein in multicellular organisms.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2007-12       Impact factor: 2.487

9.  p63 promotes cell survival through fatty acid synthase.

Authors:  Venkata Sabbisetti; Arianna Di Napoli; Apryle Seeley; Angela M Amato; Esther O'Regan; Musie Ghebremichael; Massimo Loda; Sabina Signoretti
Journal:  PLoS One       Date:  2009-06-11       Impact factor: 3.240

10.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.